Aclaris Therapeutics, Inc. (ACRS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 5.32 |
| Open | 5.3 |
| Day High | 5.34 |
| Day Low | 5.1 |
| 52-Week High | 5.88 |
| 52-Week Low | 1.5 |
| Volume | 1.64M |
| Average Volume | 1.65M |
| Market Cap | 726.25M |
| PE | -9.29 |
| EPS | -0.56 |
| Moving Average 50 Days | 4.97 |
| Moving Average 200 Days | 3.74 |
| Change | -0.12 |
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday Ma
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiat
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi